R. Siegel, D. Naishadham, A. J. Jemal3-]-a, C. N. Ziebarth, J. Landen et al., Cancer statistics Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges Primary ovarian cancer chemotherapy: current standards of care Major clinical research advances in gynecologic cancer in 2011 Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer, Cancer J. Clin. C.A. Cancer J. Clin. Clin. Obstet. Gynecol. Br. J. Cancer. J. Gynecol. Oncol. Mol. Ther, vol.59, issue.106, pp.225-249, 2003.

D. K. Markman, F. Armstrong, W. P. Muggia, and . Mcguire, Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study, Classe, I. Jaffre, J.S. Frenel, V. Bordes, M. Dejode, F. Dravet, G. Ferron, F, pp.3621-3627, 2007.

D. B. Marchal, D. Rigaud, L. Loussouarn, F. Campion, F. Galtier-dereure et al., Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1, Eur. J. Surg. Oncol. J. Clin. Endocrinol. Metab, vol.37, issue.756, pp.971-977, 1992.

W. R. Miller and S. P. Langdon, Steroid hormones and cancer: (II) lessons from experimental system, European Journal of Surgical Oncology (EJSO), vol.23, issue.1, pp.72-83, 1997.
DOI : 10.1016/S0748-7983(97)80148-5

H. Argraves and . Rochefort, Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells, Proc. Natl. Acad. Sci. U.S.A, vol.93, issue.1, pp.316-320, 1996.

S. Cunat, P. Hoffmann, and P. , Estrogens and epithelial ovarian cancer, Gynecologic Oncology, vol.94, issue.1, pp.25-32, 2004.
DOI : 10.1016/j.ygyno.2004.03.026

P. Roger, P. Pujol, A. Lucas, P. Baldet, and H. Rochefort, Increased Immunostaining of Fibulin-1, an Estrogen-Regulated Protein in the Stroma of Human Ovarian Epithelial Tumors, The American Journal of Pathology, vol.153, issue.5, pp.1579-1588, 1998.
DOI : 10.1016/S0002-9440(10)65746-X

B. J. Slotman and B. R. Rao, Ovarian cancer (review) Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy, Anticancer Res, vol.8, issue.3, pp.417-434, 1988.

. Maudelonde, Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis, Cancer Res, vol.58, issue.23, pp.5367-5373, 1998.

J. L. Perez-gracia and E. M. Carrasco, Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future Research, Gynecologic Oncology, vol.84, issue.2, pp.201-209, 2002.
DOI : 10.1006/gyno.2001.6489

M. Markman, K. A. Iseminger, K. D. Hatch, W. T. Creasman, W. Barnes et al., Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report, Gynecologic Oncology, vol.62, issue.1, pp.4-6, 1996.
DOI : 10.1006/gyno.1996.0181

C. Trope, C. Marth, and J. Kaern, Tamoxifen in the treatment of recurrent ovarian carcinoma, European Journal of Cancer, vol.36, issue.4, pp.59-61, 2000.
DOI : 10.1016/S0959-8049(00)00228-8

Y. F. Li, W. Hu, S. Q. Fu, J. D. Li, J. H. Liu et al., Aromatase inhibitors in ovarian cancer: is there a role?, International Journal of Gynecological Cancer, vol.18, issue.4, pp.600-614, 2008.
DOI : 10.1111/j.1525-1438.2007.01075.x

C. A. Papadimitriou, S. Markaki, J. Siapkaras, G. Vlachos, E. Efstathiou et al., Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer, Oncology, vol.66, issue.2, pp.112-117, 2004.
DOI : 10.1159/000077436

P. A. Argenta, S. G. Thomas, P. L. Judson, L. S. Downs, J. et al., A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer, Gynecologic Oncology, vol.113, issue.2, pp.205-209, 2009.
DOI : 10.1016/j.ygyno.2009.01.012

R. Kothari, P. Argenta, J. Fowler, J. Carter, and W. Shimp, Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature, Archive of oncology, vol.18, issue.1-2, pp.32-35, 2010.
DOI : 10.2298/AOO1002032K

B. R. Rao and B. J. Slotman, Endocrine Factors in Common Epithelial Ovarian Cancer*, Endocrine Reviews, vol.12, issue.1, pp.14-26, 1991.
DOI : 10.1210/edrv-12-1-14

K. D. Hatch, J. B. Beecham, J. A. Blessing, and W. T. Creasman, Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patients, Cancer, vol.4, issue.2, pp.269-271, 1991.
DOI : 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O

R. B. Riggins, R. S. Schrecengost, M. S. Guerrero, and A. H. Bouton, Pathways to tamoxifen resistance, Cancer Letters, vol.256, issue.1, pp.1-24, 2007.
DOI : 10.1016/j.canlet.2007.03.016

R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar, Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacol. Rev, vol.53, issue.1, pp.25-71, 2001.

E. Badia, J. Oliva, P. Balaguer, and V. Cavailles, Tamoxifen Resistance and Epigenetic Modifications in Breast Cancer Cell Lines, Current Medicinal Chemistry, vol.14, issue.28, pp.3035-3045, 2007.
DOI : 10.2174/092986707782794023
URL : https://hal.archives-ouvertes.fr/inserm-00230236

R. Zhou, O. Treeck, F. Horn, and O. Ortmann, Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells, Gynecologic Oncology, vol.96, issue.3, pp.678-683, 2005.
DOI : 10.1016/j.ygyno.2004.11.023

K. R. Geisinger, T. E. Kute, M. J. Pettenati, C. E. Welander, Y. Dennard et al., Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors, Cancer, vol.44, issue.2, pp.280-288, 1989.
DOI : 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N

C. Donaghue, B. R. Westley, and F. E. May, Selective promoter usage of the human estrogen receptor-alpha gene and its regulation by estrogen, Mol. Endocrinol, vol.13, issue.11, pp.1934-1950, 1999.

V. Duong, N. Boulle, S. Daujat, J. Chauvet, S. Bonnet et al., Differential Regulation of Estrogen Receptor ?? Turnover and Transactivation by Mdm2 and Stress-Inducing Agents, Cancer Research, vol.67, issue.11, pp.5513-5521, 2007.
DOI : 10.1158/0008-5472.CAN-07-0967
URL : https://hal.archives-ouvertes.fr/inserm-00157234

R. A. Montano and . Keri, FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis, Development, vol.137, issue.12, pp.2045-2054, 2010.

J. Eeckhoute, E. K. Keeton, M. Lupien, S. A. Krum, J. S. Carroll et al., Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor ?? Expression in Breast Cancer, Cancer Research, vol.67, issue.13, pp.6477-6483, 2007.
DOI : 10.1158/0008-5472.CAN-07-0746

M. Kos, G. Reid, S. Denger, and F. Gannon, Minireview: Genomic Organization of the Human ER?? Gene Promoter Region, Molecular Endocrinology, vol.15, issue.12, pp.2057-2063, 2001.
DOI : 10.1210/me.15.12.2057

G. Reid, S. Denger, M. Kos, and F. Gannon, Human estrogen receptor-??: regulation by synthesis, modification and degradation, Cellular and Molecular Life Sciences (CMLS), vol.59, issue.5, pp.821-831, 2002.
DOI : 10.1007/s00018-002-8470-2

K. Grandien, M. Backdahl, O. Ljunggren, J. A. Gustafsson, and A. Berkenstam, Estrogen target tissue determines alternative promoter utilization of the human estrogen receptor gene in osteoblasts and tumor cell lines, Endocrinology, vol.136, issue.5, pp.2223-2229, 1995.

R. J. Weigel, D. L. Crooks, J. D. Iglehart, and E. C. Deconinck, Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma, Cell. Growth Differ, vol.6, issue.6, pp.707-711, 1995.

G. G. Rao and D. S. Miller, Hormonal therapy in epithelial ovarian cancer, Expert Review of Anticancer Therapy, vol.6, issue.1, pp.43-47, 2006.
DOI : 10.1586/14737140.6.1.43

P. Daniel, S. J. Gaskell, H. Bishop, C. Campbell, and R. I. Nicholson, Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma, European Journal of Cancer and Clinical Oncology, vol.17, issue.11, pp.1183-1189, 1981.
DOI : 10.1016/S0277-5379(81)80022-3

J. Maccallum, J. Cummings, J. M. Dixon, and W. R. Miller, Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours, Br. J. Cancer, vol.82, issue.10, pp.1629-1635, 2000.

K. Mahoney, K. J. Shioda, S. Isselbacher, T. Ramaswamy, and . Shioda, Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drugresistant progenitor, Proc. Natl. Acad. Sci. U.S.A, vol.106, issue.34, pp.14536-14541, 2009.

J. L. Borgna and H. Rochefort, Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues, J. Biol. Chem, vol.256, issue.2, pp.859-868, 1981.

E. Coezy, J. L. Borgna, and H. Rochefort, Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth, Cancer Res, vol.42, issue.1, pp.317-323, 1982.

J. F. Robertson, (Fulvestrant)--the first oestrogen receptor down-regulator-current clinical data, Br. J. Cancer, vol.182, issue.85 2, pp.780-791, 2001.

C. K. Osborne, A. Wakeling, and R. I. Nicholson, Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action, British Journal of Cancer, vol.90, pp.2-6, 2004.
DOI : 10.1038/sj.bjc.6601629

J. A. Robertson, Y. Zhang, and N. H. Ing, ICI 182,780 acts as a partial agonist and antagonist of estradiol effects in specific cells of the sheep uterus, The Journal of Steroid Biochemistry and Molecular Biology, vol.77, issue.4-5
DOI : 10.1016/S0960-0760(01)00061-9

H. Varma and S. E. Conrad, Antiestrogen ICI 182,780 decreases proliferation of insulinlike growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling, Cancer Res, vol.62, issue.14, pp.3985-3991, 2002.

K. Leblanc, E. Sexton, S. Parent, G. Belanger, M. C. Dery et al., Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens, Int. J. Oncol, vol.30, issue.2, pp.477-487, 2007.

. Badve, FOXA1 is an independent prognostic marker for ER-positive breast cancer, Breast Cancer Res. Treat, 2011.

S. H. Park, K. Y. Kim, B. S. An, J. H. Choi, E. B. Jeung et al., Cell Growth of Ovarian Cancer Cells is Stimulated by Xenoestrogens through an Estrogen-Dependent Pathway, but Their Stimulation of Cell Growth Appears not to be Involved in the Activation of the Mitogen-Activated Protein Kinases ERK-1 and p38, Journal of Reproduction and Development, vol.55, issue.1, pp.23-29, 2009.
DOI : 10.1262/jrd.20094

A. T. Ferguson, R. G. Lapidus, S. B. Baylin, and N. E. Davidson, Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression, Cancer Res, vol.55, issue.11, pp.2279-2283, 1995.

M. Nicolas and . Pons, Hydroxytamoxifen induces a rapid and irreversible inactivation of an estrogenic response in an MCF-7-derived cell line, Cancer Res, vol.54, pp.22-5860, 1994.

E. Badia, M. J. Duchesne, J. C. Nicolas, and M. Pons, Rapid tamoxifen-induced inactivation of an estrogenic response is accompanied by a localized epigenetic modification but not by mutations, Breast Cancer Research and Treatment, vol.193, issue.1, pp.71-81, 1998.
DOI : 10.1023/A:1005801005966

J. Oliva, S. Messaoudi, F. Pellestor, M. Fuentes, V. Georget et al., Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells, E.B.S. Lett, issue.20, pp.579-4278, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00016567

M. A. Tessel, N. L. Krett, and S. T. Rosen, Steroid receptor and microRNA regulation in cancer, Current Opinion in Oncology, vol.22, issue.6, pp.592-597, 2010.
DOI : 10.1097/CCO.0b013e32833ea80c

B. D. Adams, H. Furneaux, and B. A. White, The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-?? (ER??) and Represses ER?? Messenger RNA and Protein Expression in Breast Cancer Cell Lines, Molecular Endocrinology, vol.21, issue.5, pp.1132-1147, 2007.
DOI : 10.1210/me.2007-0022

C. M. Ivan, K. P. Croce, and . Nephew, MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways, Oncogene, vol.30, issue.9, pp.1082-1097, 2011.